Press Releases Archive
SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue
Wider range of prospective patients in the UK, Canada and the US for continued clinical study
Subscription period postponed for the rights issue. Other conditions remain unchanged
SpectraCure's MSEK 140 rights issue of units is fully guaranteed
Patent application enters PCT phase, SpectraCure ensures development and work
New study underway in the US and approval from the Food and Drug Administration (FDA)
Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27
The FDA's initiative can provide faster market access for SpectraCure
SpectraCure reports positive results from the company's clinical phase 1-study
Final preparation for Phase 2 - SpectraCure extends contract with hospital in London
SpectraCure receives prestigious grant from the Eurostars program
SpectraCure one step closer to Phase 2 after successful treatment effect in recent patients
The ethics committee in London gives approval to start clinical study
Results and strategies of the clinical studies were discussed with the responsible physician
SpectraCure presents the company and the progress on their current clinical trial
The CEO of SpectraCure increases his shareholding through MK Capital
SpectraCure initiates a joint project with German company MedCom GmbH
The first day of trading with warrants of series TO2 is estimated at 27 January 2017